Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study BioPharma DiveThe therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said.Clinical DataImmunology & InflammationRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive The therapy, which works similarly to Takeda s blockbuster Entyvio, showed remission rates that suggest a best-in-class profile, the company said. Clinical DataImmunology & InflammationRead full story Post navigation Previous: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphomaNext: Alamar, Hemab, Kailera, and Seaport advance IPOs Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
